Interactions between corticosteroids and β2-agonists

Clinical Reviews in Allergy and Immunology

Volumn 31, Issue 2-3, 2006, Pages 231-245

  Hancox, Robert J ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b WAIKATO HOSPITAL   (New Zealand)

Author keywords

Corticosteroid; Interaction; Synergy; Agonist

Indexed keywords

ALLERGEN; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FENOTEROL; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; ISOPRENALINE; LONG ACTING DRUG; METHACHOLINE; NITRIC OXIDE; PLACEBO; PREDNISOLONE; SALMETEROL; SHORT ACTING DRUG; TERBUTALINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

AIRWAY; ASTHMA; BRONCHODILATATION; BRONCHUS BIOPSY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG DOSAGE FORM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; EOSINOPHIL; FORCED EXPIRATORY VOLUME; HUMAN; INHALER; LUNG FUNCTION; LUNG LAVAGE; MAST CELL; META ANALYSIS; NONHUMAN; PEAK EXPIRATORY FLOW; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; DRUG COMBINATION; DRUG INTERACTION;

ADRENERGIC BETA-AGONISTS; ASTHMA; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; RECEPTORS, ADRENERGIC, BETA-2;

EID: 33751345532     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1385/CRIAI:31:2:231     Document Type: Review

References (104)

1. 2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 285, 2583-2593.
2. Lemanske, R. F. Jr, Sorkness C. A., Mauger E. A., et al. (2001), Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 285, 2594-2603.
3. Nelson, Harold S., Weiss, Scott T., Bleecker, Eugene R., et al. (2006), The Salmeterol Multicenter Asthma Research Trial: A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol. Chest 129, 15-26.
4. Pauwels, R. A., Lofdahl C. G., Postma D. S., et al. (1997), Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 337, 1405-1411.
5. Ni, C. M., Greenstone I., Danish A., et al. (2005), Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst. Rev. CD005535.
6. Bateman, E. D., Boushey H. A., Bousquet J., et al. (2004), Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med. 170, 836-844.
7. Hancox, R. J. and Taylor D. R. (2001), Long-acting beta-agonist treatment in patients with persistent asthma already receiving inhaled corticosteroids. BioDrugs 15, 11-24.
8. British Thoracic Society, Scottish Intercollegiate Guidelines Network. (2003), British guideline on the management of asthma. Thorax 58, 1-83.
9. Workshop Report, Global Strategy for Asthma Management and Prevention. (2005), http://www.ginasthma.org/ Accessed January 21, 2006.
10. Calverley, P., Pauwels R., Vestbo J., et al. (2003), Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361, 449-456.
11. Szafranski, W., Cukier A., Ramirez A., et al. (2003), Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 21, 74-81.
12. Nannini, L., Cates C. J., Lasserson T. J., and Poole P. (2004), Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. CD003794.
13. Peachell, P. (2005), Targeting the mast cell in asthma. Curr. Opin. Pharmacol. 5, 251-256.
14. 2-agonists and corticosteroids. Eur. Respir. J. 19, 182-191.
15. Remington, T. L. and Digiovine B. (2005), Long-acting beta-agonists: anti-inflammatory properties and synergy with corticosteroids in asthma. Curr. Opin. Pulm. Med. 11, 74-78.
16. Currie, G. P., Stenback S., and Lipworth B. J. (2003), Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma. Br. J. Clin. Pharmacol. 56, 11-17.
17. 2-agonists in asthma and chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 1, 200-206.
18. 2-agonists in asthma. Respir. Med. 99, 683-694.
19. Taylor, D. R. and Hancox R. J. (2000), Interactions between corticosteroids and beta agonists. Thorax 55, 595-602.
20. Hadcock, J. R. and Malbon C. C. (1988), Regulation of beta-adrenergic receptors by "permissive" hormones: glucocorticoids increase steady-state levels of receptor mRNA. Proc. Natl. Acad. Sci. USA 85, 8415-8419.
21. 2-adrenergic receptor function in human nasal mucosa. Am. J. Respir. Crit. Care Med. 155, 704-710.
22. 2-adrenergic receptor gene are obligate for glucocorticoid regulation of receptor mRNA levels. Biochem. Biophys. Res. Commun. 154, 676-681.
23. 2-adrenergic receptor transcription in human lung. Am. J. Physiol. 268, L41-L46.
24. Hui, K. K., Conolly M. E., and Tashkin D. P. (1982), Reversal of human lymphocyte beta-adrenoceptor desensitization by glucocorticoids. Clin. Pharmacol. Ther. 32, 566-571.
25. Peters, M. J., Adcock I. M., Brown C. R., and Barnes P. J. (1993), Beta-agonist inhibition of steroid-receptor DNA-binding activity in human lung. Am. Rev. Respir. Dis. 147, A772.
26. Adcock, I. M., Brown C. R., Gelder C. M., Shirasaki H., Peters M. J., and Barnes P. J. (1995), Effects of glucocorticoids on transcription factor activation in human peripheral blood mononuclear cells. Am. J. Physiol. 268, C331-C338.
27. Peters, M. J., Adcock I. M., Brown C. R., and Barnes P. J. (1995), Beta-adrenoceptor agonists interfere with glucocorticoid receptor DNA binding in rat lung. Eur. J. Pharmacol. 289, 275-281.
28. 2-agonists: alpha and beta glucocorticoid-receptor mRNA expression in human bronchial epithelial cells. Biochem. Pharmacol. 56, 1561-1569.
29. Nielson, C. P. and Hadjokas N. E. (1998), Beta-adrenoceptor agonists block corticosteroid inhibition in eosinophils. Am. J. Respir. Crit. Care Med. 157, 184-191.
30. Tse, R., Marroquin B. A., Dorscheid D. R., and White S. R. (2003), Beta-adrenergic agonists inhibit corticosteroid-induced apoptosis of airway epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 285, L393-L404.
31. Vanacker, N. J., Palmans E., Pauwels R. A., and Kips J. C. (2002), Effect of combining salmeterol and fluticasone on the progression of airway remodeling. Am. J. Respir. Crit. Care Med. 166, 1128-1134.
32. Oddera, S., Silvestri M., Testi R., and Rossi G. A. (1998), Salmeterol enhances the inhibitory activity of dexamethasone on allergen-induced blood mononuclear cell activation. Respiration 65, 199-204.
33. Profita, M., Gagliardo R., Di Giorgi R., et al. (2005), Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics. Allergy 60, 323-329.
34. Pang, L. and Knox A. J. (2000), Synergistic inhibition by beta(2)-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells. Am. J. Respir. Cell Mol. Biol. 23, 79-85.
35. Pang, L. and Knox A. J. (2001), Regulation of TNF-alpha-induced eotaxin release from cultured human airway smooth muscle cells by beta2-agonists and corticosteroids. FASEB J. 15, 261-269.
36. Korn, S. H., Jerre A., and Brattsand R. (2001), Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells. Eur. Respir. J. 17, 1070-1077.
37. 2-Adrenoceptor agonists, like glucocorticoids, repress eotaxin gene transcription by selective inhibition of histone H4 acetylation. J. Immunol. 175, 478-486.
38. Oddera, S., Silvestri M., Lantero S., Sacco O., and Rossi G. A. (1998), Downregulation of the expression of intercellular adhesion molecule (ICAM)-1 on bronchial epithelial cells by fenoterol, a beta2-adrenoceptor agonist. J. Asthma. 35, 401-408.
39. Silvestri, M., Fregonese L., Sabatini F., Dasic G., and Rossi G. A. (2001), Fluticasone and salmeterol downregulate in vitro, fibroblast proliferation and ICAM-1 or H-CAM expression. Eur. Respir. J. 18, 139-145.
40. Pace, E., Gagliardo R., Melis M., et al. (2004), Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma. J. Allergy Clin. Immunol. 114, 1216-1223.
41. Dong, Y., Aronsson M., Gustafsson J. A., and Okret S. (1989), The mechanism of cAMP-induced glucocorticoid receptor expression. Correlation to cellular glucocorticoid response. J. Biol. Chem. 264, 13,679-13,683.
42. 2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J. Biol. Chem. 274, 1005-1010.
43. 2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 360, 1293-1299.
44. Losel, R. M., Falkenstein E., Feuring M., et al. (2003), Nongenomic steroid action: controversies, questions, and answers. Physiol. Rev. 83, 965-1016.
45. 2-adrenergic receptor function, response, and regulation. J. Allergy Clin. Immunol. 117, 18-24.
46. Torphy, T. J. (1994), Beta-adrenoceptors, cAMP and airway smooth muscle relaxation: challenges to the dogma. Trends Pharmacol. Sci. 15, 370-374.
47. Usmani, O. S., Ito K., Maneechotesuwan K., et al. (2005), Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am. J. Respir. Crit. Care Med. 172, 704-712.
48. Lee, D. K., Jackson C. M., Currie G. P., Cockburn W. J., and Lipworth B. J. (2003), Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma. Br. J. Clin. Pharmacol. 56, 494-500.
49. Aziz, I., Wilson A. M., and Lipworth B. J. (2000), Effects of once-daily formoterol and budesonide given alone or in combination on surrogate inflammatory markers in asthmatic adults. Chest 118, 1049-1058.
50. Gardiner, P. V., Ward C., Booth H., Allison A., Hendrick D. J., and Walters E. H. (1994), Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am. J. Respir. Crit. Care Med. 150, 1006-1011.
51. Overbeek, S. E., Mulder P. G., Baelemans S. M., Hoogsteden H. C., and Prins J. B. (2005), Formoterol added to low-dose budesonide has no additional antiinflammatory effect in asthmatic patients. Chest 128, 1121-1127.
52. Greening, A. P., Ind P. W., Northfield M., and Shaw G. (1994), Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 344, 219-224.
53. Woolcock, A., Lundback B., Ringdal N., and Jacques L. A. (1996), Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am. J. Respir. Crit. Care Med. 153, 1481-1488.
54. Kips, J. C., O'Connor B. J., Inman M. D., et al. (2000), A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am. J. Respir. Crit. Care Med. 161, 996-1001.
55. Currie, G. P., Bates C. E., Lee D. K., Jackson C. M., and Lipworth B. J. (2003), Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. Eur. J. Clin. Pharmacol. 59, 11-15.
56. 2 agonist, inhaled corticosteroid and their combination in the treatment of asthma. Thorax 54, 482-487.
57. Aldridge, R. E., Hancox R. J., Taylor D.R., et al. (2000), Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am. J. Respir. Crit. Care Med. 161, 1459-1464.
58. Hancox, R. J., Stevens D. A., Adcock I. M., Barnes P. J., and Taylor D. R. (1999), Effects of inhaled beta agonist and corticosteroid treatment on nuclear transcription factors in bronchial mucosa in asthma. Thorax 54, 488-492.
59. Li, X., Ward C., Thien F., et al. (1999), An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am. J. Respir. Crit. Care Med. 160, 1493-1499.
60. Wallin, A., Sue-Chu M., Bjermer L., et al. (2003), Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. J. Allergy Clin. Immunol. 112, 72-78.
61. Wallin, A., Sandstrom T., Soderberg M., et al. (1999), The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. Am. J. Respir. Crit. Care Med. 159, 79-86.
62. Davies, A. O., De Lean A., and Lefkowitz R. J. (1981), Myocardial beta-adrenergic receptors from adrenalectomized rats: impaired formation of high-affinity agonist-receptor complexes. Endocrinology 108, 720-722.
63. Davies, A. O. and Lefkowitz R. J. (1984), Regulation of beta-adrenergic receptors by steroid hormones. Annu. Rev. Physiol. 46, 119-130.
64. Shenfield, G. M., Hodson M. E., Clarke S. W., and Paterson J. W. (1975), Interaction of corticosteroids and catecholamines in the treatment of asthma. Thorax 30, 430-435.
65. 2-receptor function in the airways and adrenal responsiveness in bronchial asthma. Eur. J. Clin. Pharmacol. 34, 577-583.
66. Wempe, J. B., Postma D. S., Breederveld N., et al. (1992), Separate and combined effects of corticosteroids and bronchodilators on airflow obstruction and airway hyperresponsiveness in asthma. J. Allergy Clin. Immunol. 89, 679-687.
67. Curzon, P. G., Martin M. A., Cooke N. J., and Muers M. F. (1983), Effect of oral prednisolone on response to salbutamol and ipratropium bromide aerosols in patients with chronic airflow obstruction. Thorax 38, 601-604.
68. Grandordy, B., Belmatoug N., Morelle A., De Lauture D., and Marsac J. (1987), Effect of betamethasone on airway obstruction and bronchial response to salbutamol in prednisolone resistant asthma. Thorax 42, 65-71.
69. Stephan, W. C., Chick T. W., Avner B. P., and Jenne J. W. (1980), Tachyphylaxis to inhaled isoproterenol and the effect of methylprednisolone in dogs. J. Allergy Clin. Immunol. 65, 105-109.
70. Geddes, B. A., Jones T. R., Dvorsky R. J., and Lefcoe N. M. (1974), Interaction of glucocorticoids and bronchodilators on isolated guinea pig tracheal and human bronchial smooth muscle. Am. Rev. Respir. Dis. 110, 420-427.
71. 2- adrenoceptors. Accelerated restoration of β-adrenoceptor responsiveness by prednisone and ketotifen. J. Clin. Invest. 76, 1096-1101.
72. 2-bronchodilators. Eur. J. Clin. Pharmacol. 34, 145-150.
73. Ellul-Micallef, R. and Fenech F. F. (1975), Effect of intravenous prednisolone in asthmatics with diminished adrenergic responsiveness. Lancet 2, 1269-1271.
74. Pansegrouw, D. F., Weich D. J., and le Roux F. P. (1991), Beta-adrenergic receptor tachyphylaxis in acute severe asthma. A preliminary communication. S. Afr. Med. J. 80, 229,230.
75. Holgate, S. T., C. J. Baldwin, and A. E. Tattersfield. (1977), beta-adrenergic agonist resistance in normal human airways. Lancet 2, 375-377.
76. Cazzola, M., Santus P., Di Marco F., et al. (2004), Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD. Pulm. Pharmacol. Ther. 17, 121-125.
77. Tan K. S., Grove A., McLean A., Gnosspelius Y., Hall I. P., Lipworth B. J. (1997), Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am. J. Respir. Crit. Care Med. 156, 28-35.
78. Lipworth, B. J. and Aziz I. (2000), Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration. Chest 117, 156-162.
79. Jones, S. L., Cowan J. O., Flannery E. M., Hancox R. J., Herbison G. P., and Taylor D. R. (2001), Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. Eur. Respir. J. 17, 368-373.
80. Hancox, R. J., Aldridge R. E., Cowan J. O., et al. (1999), Tolerance to beta-agonists during acute bronchoconstriction. Eur. Respir. J. 14, 283-287.
81. Yates, D. H., Kharitonov S. A., and Barnes P. J. (1996), An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist. Am. J. Respir. Crit. Care Med. 154, 1603-1607.
82. Booth, H., Bish R., Walters J., Whitehead F., and Walters E. H. (1996), Salmeterol tachyphylaxis in steroid treated asthmatic subjects. Thorax 51, 1100-1104.
83. Kalra, S., Swystun V. A., Bhagat R., and Cockcroft D. W. (1996), Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 109, 953-956.
84. Simons, F. E., Gerstner T. V., and Cheang M. S. (1997), Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 99, 655-659.
85. Boulet, L. P., Cartier A., Milot J., Cote J., Malo J. L., and Laviolette M. (1998), Tolerance to the protective effects of salmeterol on methacholine-induced bronchoconstriction: influence of inhaled corticosteroids. Eur. Respir. J. 11, 1091-1097.
86. Aziz, I., Tan K. S., Hall I. P., Devlin M. M., and Lipworth B. J. (1998), Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol. Eur. Respir. J. 12, 580-584.
87. Grootendorst, D. C., Sterk P. J., and Heijerman H. G. (2001), Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma. Eur. Respir. J. 17, 374-379.
88. Yates, D. H., Worsdell M., and Barnes P. J. (1998), Effect of an inhaled glucocorticosteroid on mast cell and smooth muscle beta2 adrenergic tolerance in mild asthma. Thorax 53, 110-113.
89. Giannini, D., Bacci E., Dente F. L., et al. (1999), Inhaled beclomethasone dipropionate reverts tolerance to the protective effect of salmeterol on allergen challenge. Chest 115, 629-634.
90. Paggiaro, P. L., Giannini D., Di Franco A., et al. (2005), Minimal tolerance to the bronchoprotective effect of inhaled salmeterol/fluticasone combination on allergene challenge. Pulm. Pharmacol. Ther. [Epub ahead of print]
91. 2-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults and children. Cochrane Database Syst. Rev. CD005076.
92. Wong, C. S., Wahedna I., Pavord I. D., and Tattersfield A. E. (1994), Effect of regular terbutaline and budesonide on bronchial reactivity to allergen challenge. Am. J. Respir. Crit. Care Med. 150, 1268-1273.
93. 2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. Am. J. Respir. Crit. Care Med. 152, 1485-1489.
94. 2-agonist therapy. Eur. J. Clin. Pharmacol. 54, 377-381.
95. 2-adrenoceptor subsensitivity induced by regular formoterol. Chest 113, 34-41.
96. Taylor, D. R., Wilkins G. T., Herbison G. P., and Flannery E. M. (1992), Interaction between corticosteroid and beta-agonist drugs. Biochemical and cardiovascular effects in normal subjects. Chest 102, 519-524.
97. Salpeter, S. R., Ormiston T. M., and Salpeter E. E. (2004), Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 125, 2309-2321.
98. Nelson, H. S., Chapman K. R., Pyke S. D., Johnson M., and Pritchard J. N. (2003), Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J. Allergy Clin. Immunol. 112, 29-36.
99. Zetterstrom, O., Buhl R., Mellem H., et al. (2001), Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur. Respir. J. 18, 262-268.
100. Rosenhall, L., Elvstrand A., Tilling B., et al. (2003), One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma. Respir. Med. 97, 702-708.
101. Wilding, P. J., Clark M. M., Oborne J., Bennett J. A., and Tattersfield A. E. (1996), Effect of regular terbutaline on the airway response to inhaled budesonide. Thorax 51, 989-992.
102. 2-agonist and steroid dry powder inhaler in asthma. Am. J. Respir. Crit. Care Med. 151, 1053-1057.
103. Taylor, D. R., Town G. I., Herbison G. P., et al. (1998), Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol. Thorax 53, 744-752.
104. Sears, M. R., Taylor D. R., Print C. G., et al. (1990), Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 336, 1391-1396.